Clinical Trial Update: IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers [Phase 2]

View source ↗

Summary

A national platform coordinating five Phase II academic trials at Lyon to assess the safety and efficacy of the domvanalimab + zimberelimab combination in advan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinomas
• Carcinoid Tumor
• Gastroenteropancreatic Neuroendocrine Tumor
• Gestational Trophoblastic Tumor
• Peritoneal Mesothelioma
• Thymoma and Thymic Carcinoma

Drugs mentioned

• Domvanalimab (domvanalimab)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Peritoneal Mesothelioma, Gestational Trophoblastic Tumor | Phase 2 | Status: RECRUITING